Stereotaxis, Inc. (STXS)
NYSEAMERICAN: STXS · IEX Real-Time Price · USD
2.410
+0.060 (2.55%)
May 1, 2024, 4:00 PM EDT - Market closed
Stereotaxis Revenue
In the year 2023, Stereotaxis had annual revenue of $26.77M, a decrease of -4.89%. Revenue in the quarter ending December 31, 2023 was $4.57M, a -37.47% decrease year-over-year.
Revenue (ttm)
$26.77M
Revenue Growth
-4.89%
P/S Ratio
7.39
Revenue / Employee
$219,434
Employees
122
Market Cap
197.93M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 26.77M | -1.38M | -4.89% |
Dec 31, 2022 | 28.15M | -6.87M | -19.63% |
Dec 31, 2021 | 35.02M | 8.39M | 31.51% |
Dec 31, 2020 | 26.63M | -2.27M | -7.86% |
Dec 31, 2019 | 28.90M | -444.07K | -1.51% |
Dec 31, 2018 | 29.35M | -1.80M | -5.77% |
Dec 31, 2017 | 31.14M | -1.02M | -3.17% |
Dec 31, 2016 | 32.16M | -5.51M | -14.63% |
Dec 31, 2015 | 37.67M | 2.66M | 7.61% |
Dec 31, 2014 | 35.01M | -3.02M | -7.94% |
Dec 31, 2013 | 38.03M | -8.53M | -18.32% |
Dec 31, 2012 | 46.56M | 4.58M | 10.90% |
Dec 31, 2011 | 41.99M | -12.06M | -22.32% |
Dec 31, 2010 | 54.05M | 2.90M | 5.67% |
Dec 31, 2009 | 51.15M | 10.78M | 26.72% |
Dec 31, 2008 | 40.37M | 1.07M | 2.71% |
Dec 31, 2007 | 39.30M | 12.11M | 44.52% |
Dec 31, 2006 | 27.19M | 12.17M | 80.96% |
Dec 31, 2005 | 15.03M | -3.79M | -20.14% |
Dec 31, 2004 | 18.82M | 13.80M | 275.22% |
Dec 31, 2003 | 5.01M | 5.00M | 26,433.74% |
Dec 31, 2002 | 18.90K | - | - |
Dec 31, 2001 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Lifecore Biomedical | 103.27M |
Akoya Biosciences | 96.63M |
Alimera Sciences | 80.75M |
Century Therapeutics | 2.24M |
Cardiff Oncology | 488.00K |
STXS News
- 9 days ago - Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024 - GlobeNewsWire
- 2 months ago - Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States - GlobeNewsWire
- 2 months ago - Stereotaxis Reports 2023 Full Year Financial Results - GlobeNewsWire
- 2 months ago - Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology - GlobeNewsWire
- 2 months ago - Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 - GlobeNewsWire
- 4 months ago - Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter - GlobeNewsWire
- 5 months ago - Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients - GlobeNewsWire
- 5 months ago - Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference - GlobeNewsWire